The course of multiple sclerosis rewritten: a Norwegian population-based study on disease demographics and progression

被引:24
|
作者
Simonsen, Cecilia Smith [1 ,3 ,4 ]
Flemmen, Heidi Oyen [2 ,5 ]
Broch, Line [1 ,3 ,4 ]
Brunborg, Cathrine [6 ]
Berg-Hansen, Pal [3 ]
Moen, Stine Marit [7 ]
Celius, Elisabeth Gulowsen [3 ,4 ]
机构
[1] Vestre Viken Hosp Trust, Dept Neurol, N-3004 Dronninggata, Drammen, Norway
[2] Hosp Telemark HF, Dept Neurol, Oslo, Norway
[3] Oslo Univ Hosp, Dept Neurol, Oslo, Norway
[4] Univ Oslo, Inst Clin Med, Oslo, Norway
[5] Univ Oslo, Inst Hlth & Soc, Oslo, Norway
[6] Oslo Univ Hosp, Oslo Ctr Biostat & Epidemiol, Res Support Serv, Oslo, Norway
[7] MS Ctr Hakadal, Gronvoll, Norway
关键词
Multiple sclerosis; Disease course; Natural history; Epidemiology; Time to EDSS 6; PLACEBO-CONTROLLED TRIAL; DIAGNOSTIC-CRITERIA; NATURAL-HISTORY; VITAMIN-D; DISABILITY; THERAPY; GUIDELINES; REVISIONS; MSBASE; PANEL;
D O I
10.1007/s00415-020-10279-7
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objectives Over the past few decades, there has been an improvement in the rate of disability progression in multiple sclerosis (MS) patients, and most studies relate this evolvement to the introduction of disease-modifying therapies. However, several other factors have changed over this period, including access to MRI and newer diagnostic criteria. The aim of this study is to investigate changes in the natural course of MS over time in a near-complete and geographically well-defined population from the south-east of Norway. Methods We examined disease progression and demographics over two decades and assessed the effect of disease-modifying therapies using linear mixed-effect models. Results In a cohort of 2097 patients, we found a significant improvement in disability as measured by the Expanded Disability Status Scale (EDSS) stratified by age, and the improvement remained significant after adjusting for time on disease-modifying medications, gender and progressive MS at onset. The time from disease onset to EDSS 6 in the total cohort was 29.8 years (95% CI 28.5-31.1) and was significantly longer in patients diagnosed after 2006 compared to patients diagnosed before. There are significant differences between patient demographics, as well as time to EDSS 6, in the near-complete, geographically well-defined population compared to an additional cohort from the capital Oslo and its suburbs. Conclusion The natural course of MS is improving, but the improvement seen in disease progression has multifaceted explanations. Our study underlines the importance of completeness of data, relevant timeframes and demographics when comparing different MS populations. Studies on incomplete populations should be interpreted with caution.
引用
收藏
页码:1330 / 1341
页数:12
相关论文
共 50 条
  • [1] The course of multiple sclerosis rewritten: a Norwegian population-based study on disease demographics and progression
    Cecilia Smith Simonsen
    Heidi Øyen Flemmen
    Line Broch
    Cathrine Brunborg
    Pål Berg-Hansen
    Stine Marit Moen
    Elisabeth Gulowsen Celius
    Journal of Neurology, 2021, 268 : 1330 - 1341
  • [2] Characterization of annual disease progression of multiple sclerosis patients: A population-based study
    Freilich, Jonatan
    Manouchehrinia, Ali
    Trusheim, Mark
    Baird, Lynn G.
    Desbiens, Sophie
    Berndt, Ernst
    Hillert, Jan
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 (06) : 786 - 794
  • [3] Multiple sclerosis survival: a population-based study in Sicily
    Ragonese, P.
    Aridon, P.
    Mazzola, M. A.
    Callari, G.
    Palmeri, B.
    Famoso, G.
    Terruso, V.
    Salemi, G.
    D'Amelio, M.
    Savettieri, G.
    EUROPEAN JOURNAL OF NEUROLOGY, 2010, 17 (03) : 391 - 397
  • [4] Generational changes in multiple sclerosis phenotype in North African immigrants in France: A population-based observational study
    Nardin, Clotilde
    Latarche, Clotilde
    Soudant, Marc
    Dahan, Camille
    Michaud, Maud
    Pittion-Vouyovitch, Sophie
    Guillemin, Francis
    Debouverie, Marc
    Mathey, Guillaume
    PLOS ONE, 2018, 13 (03):
  • [5] Clinical and radiological activity of secondary progressive multiple sclerosis in a population-based cohort
    Mathey, Guillaume
    Ancel, Thomas
    Garot, Teresa
    Soudant, Marc
    Pittion-Vouyovitch, Sophie
    Guillemin, Francis
    Debouverie, Marc
    Epstein, Jonathan
    EUROPEAN JOURNAL OF NEUROLOGY, 2021, 28 (07) : 2238 - 2248
  • [6] Early High Efficacy Treatment in Multiple Sclerosis Is the Best Predictor of Future Disease Activity Over 1 and 2 Years in a Norwegian Population-Based Registry
    Simonsen, Cecilia Smith
    Flemmen, Heidi Oyen
    Broch, Line
    Brunborg, Cathrine
    Berg-Hansen, Pal
    Moen, Stine Marit
    Celius, Elisabeth Gulowsen
    FRONTIERS IN NEUROLOGY, 2021, 12
  • [7] Clinical predictors of disease progression in multiple sclerosis patients with relapsing onset in a nation-wide cohort
    Alroughani, R. A.
    Akhtar, S.
    Ahmed, S. F.
    Al-Hashel, J. Y.
    INTERNATIONAL JOURNAL OF NEUROSCIENCE, 2015, 125 (11) : 831 - 837
  • [8] Disease progression among multiple sclerosis patients before and during a disease-modifying drug program: a longitudinal population-based evaluation
    Veugelers, P. J.
    Fisk, J. D.
    Brown, M. G.
    Stadnyk, K.
    Sketris, I. S.
    Murray, T. J.
    Bhan, V.
    MULTIPLE SCLEROSIS JOURNAL, 2009, 15 (11) : 1286 - 1294
  • [9] Natural history of multiple sclerosis in a population-based cohort
    Debouverie, M.
    Pittion-Vouyovitch, S.
    Louis, S.
    Guillemin, F.
    EUROPEAN JOURNAL OF NEUROLOGY, 2008, 15 (09) : 916 - 921
  • [10] Incidence of multiple sclerosis in Iceland, 2002-2007: a population-based study
    Eliasdottir, Olof Jona
    Olafsson, Elias
    Kjartansson, Olafur
    MULTIPLE SCLEROSIS JOURNAL, 2011, 17 (08) : 909 - 913